FrançaisParis, France and Camberley, UK – 28 January 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited revenues for the year ended 31 December 2019 and provides an operational update. The Company will report its full year results in April 2020. http://novacyt.com/wp-content/uploads/2020/01/Novacyt-full-year-trading-and-operational-update-ENGLISH.pdf
Visit PageCategory: Uncategorized
Primerdesign partners with VGS Group in France
Commercial agreement includes molecular diagnostics for the growing aquaculture and aquamarine market Paris, France and Camberley, UK – 17 January 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its molecular testing division, Primerdesign Ltd (“Primerdesign”), has signed an exclusive commercial agreement with Atothis SARL, part of VGS Invest
Visit PageLiquidity Agreement Monthly Update and Total Voting Rights
Paris, France and Camberley, UK – 2 January 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised
Visit Page